TWI873187B - 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 - Google Patents
作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 Download PDFInfo
- Publication number
- TWI873187B TWI873187B TW109132483A TW109132483A TWI873187B TW I873187 B TWI873187 B TW I873187B TW 109132483 A TW109132483 A TW 109132483A TW 109132483 A TW109132483 A TW 109132483A TW I873187 B TWI873187 B TW I873187B
- Authority
- TW
- Taiwan
- Prior art keywords
- difluoromethyl
- thiadiazol
- amino
- indazol
- sulfonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903438P | 2019-09-20 | 2019-09-20 | |
| US62/903,438 | 2019-09-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202120501A TW202120501A (zh) | 2021-06-01 |
| TWI873187B true TWI873187B (zh) | 2025-02-21 |
Family
ID=72744866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109132483A TWI873187B (zh) | 2019-09-20 | 2020-09-18 | 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389003A1 (https=) |
| EP (1) | EP4031249A1 (https=) |
| JP (2) | JP2022548690A (https=) |
| KR (1) | KR20220066922A (https=) |
| CN (1) | CN114555593A (https=) |
| AU (1) | AU2020348489A1 (https=) |
| BR (1) | BR112022004624A2 (https=) |
| CA (1) | CA3147493A1 (https=) |
| IL (1) | IL291436A (https=) |
| MX (1) | MX2022003276A (https=) |
| TW (1) | TWI873187B (https=) |
| WO (1) | WO2021055744A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| EP4479387A1 (en) | 2022-02-14 | 2024-12-25 | ARase Therapeutics Inc. | Inhibitors of parg |
| CN116693519A (zh) * | 2022-03-04 | 2023-09-05 | 上海璎黎药业有限公司 | 一种含五元杂芳环结构化合物、其药物组合物及应用 |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| MX2024011545A (es) * | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg. |
| AU2023263181A1 (en) * | 2022-04-28 | 2024-10-31 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| CN119403803A (zh) | 2022-05-17 | 2025-02-07 | 858治疗公司 | Parg抑制剂 |
| TW202409036A (zh) * | 2022-05-17 | 2024-03-01 | 美商858療法股份有限公司 | Parg抑制劑 |
| TWI878939B (zh) * | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| CN119522220A (zh) | 2022-07-19 | 2025-02-25 | 苏州信诺维医药科技股份有限公司 | 含硫杂芳环化合物、其药物组合物及其用途 |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| KR20250073643A (ko) | 2022-10-03 | 2025-05-27 | 포알엑스 테라퓨틱스 아게 | Parg 억제 화합물 |
| CN120051465A (zh) * | 2022-10-13 | 2025-05-27 | 韩美药品株式会社 | 用于抑制yap-tead交互作用的新颖杂双环化合物及包含其的药学组成物 |
| EP4646208A1 (en) | 2023-01-06 | 2025-11-12 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024173453A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173524A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173514A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024173530A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| EP4688159A1 (en) | 2023-04-05 | 2026-02-11 | FoRx Therapeutics AG | Parg inhibitory compounds |
| AU2024253809A1 (en) | 2023-04-05 | 2025-10-16 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| KR20260005337A (ko) * | 2023-04-27 | 2026-01-09 | 다나틀라스 파마슈티컬즈 씨오., 엘티디. | 트리시클릭 헤테로시클릭 유도체 및 이의 조성물과 응용 |
| CN119143747A (zh) * | 2023-06-16 | 2024-12-17 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) * | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| CN119708015A (zh) * | 2023-09-28 | 2025-03-28 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| CN121889393A (zh) | 2023-10-03 | 2026-04-17 | 福克斯治疗股份公司 | Parg抑制化合物 |
| CN119859145A (zh) * | 2023-10-20 | 2025-04-22 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| WO2025087409A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025111339A1 (en) * | 2023-11-21 | 2025-05-30 | 858 Therapeutics, Inc. | Treatment of cancer with a parg inhibitor |
| AR134429A1 (es) * | 2023-11-22 | 2026-01-14 | 858 Therapeutics Inc | Inhibidores de parg |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133191A1 (en) * | 2023-12-22 | 2025-06-26 | Genecode | Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| CN118459452B (zh) * | 2024-07-10 | 2024-10-25 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2026026739A1 (zh) * | 2024-07-29 | 2026-02-05 | 海思科医药集团股份有限公司 | 一种磺酰胺化合物及其在医药上的应用 |
| WO2026032385A1 (zh) * | 2024-08-07 | 2026-02-12 | 上海亚虹医药科技有限公司 | 多聚adp核糖水解酶抑制剂及其医药用途 |
| WO2026040953A1 (zh) * | 2024-08-19 | 2026-02-26 | 上海和誉生物医药科技有限公司 | 一种多环parg抑制剂和其应用 |
| US20260055095A1 (en) * | 2024-08-23 | 2026-02-26 | Recursion Pharmaceuticals, Inc. | Novel compounds and uses thereof |
| WO2026062066A1 (en) | 2024-09-17 | 2026-03-26 | Forx Therapeutics Ag | Compounds inducing parg degradation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016097749A1 (en) * | 2014-12-19 | 2016-06-23 | Cancer Research Technology Limited | Parg inhibitory compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| AU2012204650A1 (en) * | 2011-01-07 | 2013-08-01 | Taiho Pharmaceutical Co., Ltd. | Novel indole or indazole derivative or salt thereof |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| WO2019079369A1 (en) * | 2017-10-19 | 2019-04-25 | Effector Therapeutics, Inc. | BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2 |
| JP7500555B2 (ja) * | 2018-10-25 | 2024-06-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| MX2024011545A (es) * | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg. |
-
2020
- 2020-09-18 JP JP2022517374A patent/JP2022548690A/ja not_active Ceased
- 2020-09-18 US US17/761,935 patent/US20220389003A1/en active Pending
- 2020-09-18 CA CA3147493A patent/CA3147493A1/en active Pending
- 2020-09-18 TW TW109132483A patent/TWI873187B/zh active
- 2020-09-18 BR BR112022004624A patent/BR112022004624A2/pt unknown
- 2020-09-18 MX MX2022003276A patent/MX2022003276A/es unknown
- 2020-09-18 KR KR1020227012903A patent/KR20220066922A/ko active Pending
- 2020-09-18 WO PCT/US2020/051486 patent/WO2021055744A1/en not_active Ceased
- 2020-09-18 AU AU2020348489A patent/AU2020348489A1/en active Pending
- 2020-09-18 CN CN202080065861.1A patent/CN114555593A/zh active Pending
- 2020-09-18 EP EP20786137.8A patent/EP4031249A1/en active Pending
-
2022
- 2022-03-16 IL IL291436A patent/IL291436A/en unknown
-
2024
- 2024-11-01 JP JP2024193094A patent/JP7781244B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016097749A1 (en) * | 2014-12-19 | 2016-06-23 | Cancer Research Technology Limited | Parg inhibitory compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3147493A1 (en) | 2021-03-25 |
| TW202120501A (zh) | 2021-06-01 |
| JP2022548690A (ja) | 2022-11-21 |
| US20220389003A1 (en) | 2022-12-08 |
| CN114555593A (zh) | 2022-05-27 |
| BR112022004624A2 (pt) | 2022-05-31 |
| IL291436A (en) | 2022-05-01 |
| JP7781244B2 (ja) | 2025-12-05 |
| KR20220066922A (ko) | 2022-05-24 |
| AU2020348489A1 (en) | 2022-05-05 |
| MX2022003276A (es) | 2022-04-11 |
| WO2021055744A1 (en) | 2021-03-25 |
| EP4031249A1 (en) | 2022-07-27 |
| JP2025016684A (ja) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI873187B (zh) | 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 | |
| JP7734586B2 (ja) | Ｓｈｐ２アンタゴニストとしてのカルボキサミド－ピリミジン誘導体 | |
| CN110650950B (zh) | 用于治疗或预防prmt5介导的疾病的化合物 | |
| EP3630749B1 (en) | 2-quinolone derived inhibitors of bcl6 | |
| AU2024200566A1 (en) | Pyridazinones as PARP7 inhibitors | |
| KR102604942B1 (ko) | 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물 | |
| CN121532183A (zh) | Kras g12s和g12c抑制剂 | |
| AU2014230814A1 (en) | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C | |
| ES2732437T3 (es) | Moduladores del receptor de CXCR7 | |
| WO2024173524A1 (en) | Heteroaryl-substituted benzimidazole compounds | |
| WO2024173453A1 (en) | Heteroaryl-substituted imidazopyridine compounds | |
| TW202334167A (zh) | 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物 | |
| WO2024173514A1 (en) | Amide and ester-substituted imidazopyridine compounds | |
| TW202417458A (zh) | 調節her2的化合物及方法 | |
| CA3205780A1 (en) | Tetrahydrothienopyrimidinesulfonamide compounds | |
| CN120858100A (zh) | 抑制性化合物 | |
| WO2023175185A1 (en) | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer | |
| CN115667228B (zh) | 杂芳类衍生物的盐、晶型及其制备方法 | |
| CN106928252A (zh) | 一种抑制rock的化合物及其制备方法与应用 | |
| WO2024173530A1 (en) | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds | |
| TW202330546A (zh) | 具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用 | |
| TWI912370B (zh) | 芳香雜環類化合物、藥物組合物及其應用 | |
| WO2024092222A1 (en) | Modulators of mas-related g-protein receptor d and related products and methods |